SI20108B - A controlled release formulation for poorly soluble basic drugs - Google Patents

A controlled release formulation for poorly soluble basic drugs Download PDF

Info

Publication number
SI20108B
SI20108B SI9720096A SI9720096A SI20108B SI 20108 B SI20108 B SI 20108B SI 9720096 A SI9720096 A SI 9720096A SI 9720096 A SI9720096 A SI 9720096A SI 20108 B SI20108 B SI 20108B
Authority
SI
Slovenia
Prior art keywords
composition
alginate
sodium
salt
water
Prior art date
Application number
SI9720096A
Other languages
English (en)
Other versions
SI20108A (sl
Inventor
Neville W Broad
Alan F Carmody
Liam C Feely
Brian C Withers
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of SI20108A publication Critical patent/SI20108A/sl
Publication of SI20108B publication Critical patent/SI20108B/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (17)

1 Patentni zahtevki 1. Trden farmacevtski sestavek z nadzorovanim sproščanjem, prilagojen za oralno dajanje, ki obsega: terapevtsko učinkovito količino vsaj enega bazičnega zdravila, ki ima topnost v vodi manjšo od 1 dela na 30 delov vode; v vodi topno alginatno sol; kompleksno sol alginske kisline, kjer je kation, ki da netopno sol, izbran iz skupine, ki sestoji iz kalcija, stroncija, železa in barija; in organske karboksilne kisline, da olajšamo raztapljanje bazičnega zdravila, pri čemer masno razmerje v vodi topne soli proti kompleksni soli alginske kisline variira od 16:1 do 1:1 in molsko razmerje karboksilne kisline proti zdravilu variira od 0,2:1 do 5:1.
2. Sestavek po zahtevku 1 v obliki tablete.
3. Sestavek po zahtevku 1 v obliki enkrat dnevnega dozirnega režima.
4. Sestavek po zahevku 1, kjer je bazično zdravilo makrolid.
5. Sestavek po zahtevku 4, kjer je makrolid klaritromicin.
6. Sestavek po zahtevku 1, kjer je v vodi topna alginatna sol natrijev alginat.
7. Sestavek po zahtevku 1, kjer je kompleksna sol alginske kisline natrijev-kalcijev alginat.
8. Sestavek po zahtevku 1, kjer je organska karboksilna kislina izbrana iz skupine, ki sestoji iz vinske, jabolčne, jantarne, glutame, glutamske, maleinske, mandljeve in citronske kisline. 2
9. Sestavek po zahtevku 8, kjer je organska karboksilna kislina citronska kislina.
10. Sestavek po zahtevku 1, kjer je masno razmerje natrijevega alginata proti natrijevem-kalcijevem alginatu okoli 16:1 do 1:1.
11. Sestavek po zahtevku 1, kjer je masno razmeje natrijevega alginata proti natrijevem-kalcijevem alginatu okoli 8:1 do 2:1.
12. Sestavek po zahtevku 1, kjer je molsko razmerje organske kisline proti bazičnemu zdravilu okoli 1:1.
13. Sestavek po zahtevku 1, kjer je bazično zdravilo izbrano iz skupine, ki sestoji iz sulfametoksazola, metronidazola, cimetidina, indapamida, atenolola in diazepama.
14. Sestavek po zahtevku 4, kjer je makrolid izbran iz skupine, ki sestoji iz eritromicina, diritromicina, azitromicina, roksitromicina in ABT-229.
15. Trden farmacevtski sestavek z nadzorovanim sproščanjem, prilagojen za oralno dajanje enkrat dnevnega dozirnega režima, ki obsega okoli 500 mg klaritromicina; od okoli 75 do 400 mg natrijevega alginata; od okoli 10 do 400 mg natrijevega-kalcijevega alginata; in okoli 128 mg citronske kisline.
16. Sestavek po zahtevku 14, ki obsega od okoli 80 do 200 mg natrijevega alginata in od okoli 10 do 40 mg natrijevega-kalcijevega alginata.
17. Sestavek po zahtevku 15, ki obsega okoli 120 mg natrijevega alginata in okoli 15 mg natrijevega-kalcijevega alginata.
SI9720096A 1997-06-11 1997-06-11 A controlled release formulation for poorly soluble basic drugs SI20108B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1997/010705 WO1998056357A1 (en) 1995-12-19 1997-06-11 A controlled release formulation for poorly soluble basic drugs

Publications (2)

Publication Number Publication Date
SI20108A SI20108A (sl) 2000-06-30
SI20108B true SI20108B (en) 2001-12-31

Family

ID=22261117

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9720096A SI20108B (en) 1997-06-11 1997-06-11 A controlled release formulation for poorly soluble basic drugs

Country Status (4)

Country Link
NO (1) NO310095B1 (sl)
SI (1) SI20108B (sl)
SK (1) SK282427B6 (sl)
WO (1) WO1998056357A1 (sl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3668000A (en) * 1999-04-29 2000-11-17 Russinsky Limited Compounds
EP1118333A1 (en) * 2000-01-18 2001-07-25 Eurand International S.P.A. Compositions with enhanced oral bioavailability
UA76967C2 (uk) * 2000-11-27 2006-10-16 Сандоз Аг Азитроміцин у формі моногідрату, фармацевтична композиція та спосіб його одержання
BR0308990A (pt) * 2002-04-03 2005-01-04 Ranbaxy Lab Ltd Composição farmacêutica de eritromicina e seus derivados com sabor mascarado e processo de sua preparação
SI21300A (sl) * 2002-10-08 2004-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Farmacevtske formulacije z alginati
CN100336511C (zh) * 2002-11-15 2007-09-12 江苏豪森药业股份有限公司 口服罗红霉素控释制剂
PL1638529T3 (pl) * 2003-06-16 2017-03-31 Andrx Pharmaceuticals, Llc. Kompozycja doustna o przedłużonym uwalnianiu
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
JP2020503269A (ja) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド 経口ウンデカン酸テストステロン療法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60163823A (ja) * 1984-02-03 1985-08-26 Taisho Pharmaceut Co Ltd 経口投与製剤
EP0188040B1 (en) * 1985-01-11 1991-08-14 Abbott Laboratories Limited Slow release solid preparation
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs

Also Published As

Publication number Publication date
SI20108A (sl) 2000-06-30
WO1998056357A1 (en) 1998-12-17
NO996161D0 (no) 1999-12-13
NO996161L (no) 1999-12-13
NO310095B1 (no) 2001-05-21
SK161299A3 (en) 2000-05-16
SK282427B6 (sk) 2002-01-07

Similar Documents

Publication Publication Date Title
SI20108B (en) A controlled release formulation for poorly soluble basic drugs
RU97112089A (ru) Твердая фармацевтическая композиция с регулируемым высвобождением лекарственного средства
UA40663C2 (uk) Тверда фармацевтична композиція з регульованим вивільненням лікарського засобу для орального вживання
US5646131A (en) Method for solubilizing drugs using cyclodextrins and carboxylic acids
JPH0434966B2 (sl)
JPH0229052B2 (sl)
RU2333745C2 (ru) Композиции с контролируемым высвобождением
HRP20010243B1 (en) Compositions containing diphosphonic acids
PL295329A1 (en) Method of improving oral administration applicability of a biological medication substance: dideoxypurin nucleoside
Zuckerman The newer macrolides: azithromycin and clarithromycin
ES2235834T3 (es) Matriz directamente comprimible para la liberacion controlada de dosis diarias unicas de claritromicina.
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
HK1058622A1 (en) Pharmaceutical form of administration for peptides, method for its production and use
KR19980702689A (ko) 알긴산나트륨 및 중탄산칼륨을 포함하는 액체 수성 약제학적조성물
CA2083385C (en) Sustained release suppository
CA2380757A1 (en) Pharmaceutical agent comprising a benzamide derivative as active ingredient
JPH1192402A (ja) 製剤組成物及びその製造方法
SK42999A3 (en) Aqueous liquid pharmaceutical formulation, process for the preparation and use thereof
AU749509B2 (en) Use of triclosan for the treatment of helicobacter pylori infections
Vandamme et al. Controlled release of levamisole from poly-(ε-caprolactone) matrices II. Effects of water-soluble polymer and iron powder incorporated into the matrices
Watson Bioavailability and bioinequivalence of drug formulations in small animals
US20050260263A1 (en) Sustained release formulation for sparingly soluble main drugs
EA199900938A1 (ru) Способ приготовления стабильного фармацевтического состава с фиксированной дозировкой из антиинфекционного агента/агентов и микроорганизмов в качестве активных ингредиентов
US20040067253A1 (en) Pharmaceutical preparation, method for its production as well as its use
YU25297A (en) A controlled release formulation for poorly soluble basic drugs

Legal Events

Date Code Title Description
IF Valid on the prs date
SP73 Change of data on owner

Owner name: BGP PRODUCTS OPERATIONS GMBH; CH

Effective date: 20160404